We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Statins Improve Results of Vascular Surgery

By HospiMedica International staff writers
Posted on 10 Dec 2008
A new study demonstrates that lipid-lowering therapies could stabilize coronary plaques and improve vascular surgery postoperative outcome. More...


Researchers at the Erasmus Medical Center (EMC; Rotterdam, The Netherlands) hypothesized that this effect was anti-inflammatory in nature, as opposed to an effect directly related to the statin's lipid-lowering efficacy. To test this conjuncture, they conducted a double blind, placebo-controlled trial, in which statin-naive patients were randomly assigned to receive either 80 mg of extended release fluvastatin or a matched placebo, starting 37 days prior to surgery; a total of 250 patients were assigned to fluvastatin and 247 to placebo. To assess the influence on inflammation markers by statin therapy interleukin-6 (IL-6) and C-reactive protein (CRP) were measured at randomization and immediately prior to surgery.

The study results showed that IL-6 and CRP concentrations remained stable in the placebo group and decreased in the fluvastatin group. The incidence of myocardial infarction (MI) in the fluvastatin and placebo allocated groups was 10.8% compared to 19%, and the incidence of the composite cardiac death and MI was 4.8% compared to 10.2%, respectively. The study was presented at the Veith Symposium, held in New York (NY, USA) during November 2008.

"Fluvastatin therapy was associated with a reduction of inflammation activity and improved postoperative cardiac outcome in elective vascular surgery patients," concluded study presenter Professor Don Poldermans, M.D., and colleagues at the Erasmus Medical Center.

Statins form a class of hypolipidemic drugs used to lower cholesterol levels in people with or at risk of cardiovascular disease. They lower cholesterol by inhibiting the enzyme HMG-CoA reductase, which is the rate-limiting enzyme of the mevalonate pathway of cholesterol synthesis. Inhibition of this enzyme in the liver stimulates low-density lipoprotein (LDL) receptors, resulting in an increased clearance of LDLs from the bloodstream and a decrease in blood cholesterol levels. The first results can be seen after one week of use and the effect is maximal after four to six weeks.

Related Links:
Erasmus Medical Center



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Syringes
Prefilled Saline Flush Syringes
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.